Coronavirus mutations in New York, California are of concern | Science | In-depth science and technology reporting | DW

Since health authorities have begun to more accurately sequence positive COVID-19 cases – that is, by genetically examining the test results – they have also found more and more mutations.

Most of those mutations are insignificant. But there are a few variants that researchers and officials are concerned about, in part because they are more contagious and because existing vaccines may be less effective at protecting against them.

A border post at the Czech-German border

No more freedom of movement. Some countries try to stop the spread of mutations by closing borders.

In addition to the variants identified in Great Britain, South Africa, and Brazil, there are two more variants of concern in the United States that apparently evolved there.

Rapid spread

In November, researchers first noticed a mutation in New York City called B.1.526. Since then, this variant has spread rapidly in the metropolis and across the state. By mid-February, it had been detected in 12% of all gene sequenced samples in New York.

This variant has also appeared in other countries, such as Denmark.

A woman in a face mask jogs in front of the Golden Gate Bridge

The California variant, CAL.20, is believed to be more contagious than the original virus, but not as dangerous as the UK variant.

The so-called California variety, first discovered in July 2020, has also spread quickly. Meanwhile, the two similar types, B.1.427 and B.1.429, of the California variant can be found in about a quarter of gene-sequenced samples in California.

What do we know about the two American variants?

So far we do not have solid reliable data on these variants. The California variant, CAL.20C, is said to be more contagious than the original SARS-CoV-2 virus. In cotton swabs from infected individuals, the viral load in the samples was found to be approximately doubled. But it is less contagious than the British mutant B.1.1.7, which has now been found in many countries, including Germany. The existing vaccines are believed to be somewhat less effective against the California virus variant, but still sufficient to protect patients from a severe course of COVID-19.

The New York virus variant, B.1.526, is similar to the South African variant B.1.351, which has already been found in more than 40 countries, and also bears resemblance to the Brazilian variants, P.1 and P.2, which have been found in more than 20 countries, most recently in the United Kingdom.

It is still unclear whether the New York variant is more contagious or dangerous and whether existing vaccines are still sufficiently effective against this variant.

New software helps in the search

Finding the respective variants is only possible if you know what to look for. Although we now know the genome of SARS-CoV-2, the virus is 29,903 nucleotides long, which is far too long to be able to quickly identify which variants could make it more infectious among the 611,000 genomes now stored in the GISAID database. .

The mutations were found using new software called Variant Database (VDB) developed at the California Institute of Technology in Pasadena by a team led by Pamela Bjorkman. It targets changes in the spike protein.

A man gets a Pap smear in Johannesburg

A mutation called E484K has been found in both the South African and Brazilian variant.

The potentially dangerous mutation E484K, present in B.1.351 and P.1, changes the receptor binding domain of the spike protein, and this is where the antibodies with the strongest neutralizing effect attack.

A cause for concern, but not for panic

The tip of the spike protein has also been changed in the New York variant. Understandably, this has caused some concern, Columbia University epidemiologist Wafaa El-Sadr told German public broadcaster ARD. “These changes may cause the spike protein to attach better. Or the virus to multiply more quickly. Or it may not be controlled by the antibodies through our vaccines,” he said.

But until detailed and robust data on the U.S. variants is available, these observations will remain speculative and there is no need to panic, said Dave Chokshi, commissioner in the Department of Health and Mental Hygiene in New York City. So far, there is no evidence to show that it spreads faster, whether it makes people sicker or if it decreases the effectiveness of the vaccine, he said.

This article has been translated from German.

Source